Fermenta FY25 Revenues INR 481.3 cr, up 39% YoY; Net Profit INR 76.4 cr vs year-ago loss
BSE: 506414
Bloomberg: FERMENTA:IN
Reuters: FERM.BO Consolidated Revenue for FY25 INR 481.3 crore , up by INR 134 crore YoY
, up by INR YoY Consolidated EBITDA for FY25 INR 121.6 crore , up 209% YoY
, up 209% YoY Q4FY25 Consolidated Revenues INR 143.7 crore , up 40% YoY; down 9% QoQ
MUMBAI, India , May 29, 2025 /PRNewswire/ — Fermenta Biotech Limited, India's leading manufacturer of premium-grade APIs, intermediates, and mixes of vitamins and minerals for the global markets, today announced that its consolidated revenue (other than from real estate) for the financial year ended 31 March 2025 was INR 427.0 crore , up 57% from the same year-ago period; EBITDA for FY25 was INR 83.3 crore against loss of INR 22.3 crore a year ago.
Key financials (consolidated) without real estate
Q4FY25
FY25
Revenue
INR 133.8 crore
(up 36% YoY, up 11% QoQ)
INR 427.0 crore
(up 57% YoY)
EBITDA
INR 32.2 crore
(up 200% YoY, up 30% QoQ)
INR 83.3 crore
(up by INR 105.6 crore YoY)
Key financials (consolidated) with real estate
Q4FY25
FY25
Revenue
INR 143.7 crore
(up 40% YoY, down 9% QoQ)
INR 481.3 crore
(up 39% YoY)
EBITDA
INR 40.8 crore
(up 280% YoY, down 26% QoQ)
INR 121.6 crore
(up 209% YoY)
Profit after tax
INR 33.3 crore
(up INR 40.5 crore YoY, down 12% QoQ)
INR 76.4 crore
(up INR 100.4 crore YoY)
EPS after exceptional item
INR 11.79
INR 26.35
Performance highlights Human nutrition volume grew by 48% over FY24
Animal nutrition volume grew by 24% over FY24
The company successfully completed validation batches for its spray dried (SD) variant of Vitamin D3 100,000 IU/g powder for human nutrition – Vitamin D3 100 SD and started qualification process with leading global customers and regulatory authorities.
The company also successfully completed commercial scale production of its plant based Vitamin D3 active ingredient using its proprietary technology developed in-house and completed validation batches of its plant based D3 in Oil and D3 spray dried powder variants for human nutrition-Vitadee Green™ 1 MIU Oil and Vitadee Green™ 100 SD and started qualification process with leading global customers and regulatory authorities.
Fermenta received letter of approval from GAIN, reinforcing its global commitment to quality and nutrition
Our German subsidiary showed standalone FY25 revenue of INR 38.2 crore , 412% growth from INR 7.5 crore a year ago, with EBITDA of INR 13.9 crore , against loss of INR 9.2 crore a year ago. Our US subsidiary showed revenue of INR 50.4 crore , up 81% from INR 27.8 crore a year ago with EBITDA at INR 0.5 crore loss, against INR 1.6 crore loss a year ago
Commenting on the results, Prashant Nagre , Managing Director, said:
'FY25 marks Fermenta's complete operational turnaround, validating our strategic focus and unwavering commitment to excellence. Strong volume recovery in our core Vitamin D3 business, successful geographic expansion across Latin America and Southeast Asia , and breakthrough innovations like Vitadee Green™—the world's first pharmacopeial-grade plant-based Vitamin D3—demonstrate our resilience and technical leadership.
With strong cash flows, improved margins across all product lines, and new value-added products gaining meaningful market traction, we've built a robust foundation for sustained growth. Our disciplined approach to capital allocation, proactive risk management, and strategic partnerships position us to capitalize on emerging opportunities while advancing our vision of top-quality global nutritional wellness for all.'
Revenue mix (consolidated)
FY25
(INR crore)
FY24
(INR crore)
YoY change (%)
Nutrition Business
Vitamin D3 – Human Nutrition
216.3
140.5
+54 %
Vitamin D3 – Animal Nutrition
94.0
38.2
+146 %
Others
40.0
38.7
+3 %
Other Business
Other APIs and
Intermediates
37.5
28.6
+31 %
Green Chemistry
Solutions / Enzymes
7.0
5.4
+30 %
Environmental
Solutions
22.2
11.8
+88 %
Other Income
19.6
20.4
-4 %
Value Unlocking
Real Estate
44.6
63.9
-30 %
Geographical revenue mix (consolidated) excluding real estate value unlocking
FY25
FY24
Change (%)
India
40 %
46 %
-6 %
Europe
27 %
20 %
+7 %
North America
17 %
13 %
+4 %
Others
16 %
20 %
-4 %
About Fermenta Biotech Limited
Fermenta Biotech Limited delivers best in class, science-backed nutritional ingredients across a wide range of market segments, including Pharmaceuticals, Dietary Supplements, Food & Beverages, and Veterinary. State-of-the-art manufacturing facilities located at Kullu (Himachal Pradesh) and Dahej (Gujarat) drive FBL's comprehensive portfolio of premium vitamins, nutritional premixes, and ingredients for Human and Animal Nutrition.
Our products and services cater to the exacting standards of the world's leading pharma, dietary supplements and food brands, and veterinary and animal feed producers for best-in-class solutions that enhance health, support preventive care, and drive life productivity. With decades of expertise at global-scale complex manufacturing, we also provide research-based custom solutions in green chemistry and environmental solutions.
Financial Statements can be accessed through this link:
Disclaimer
No representation or warranty, express or implied, is made as to, and no reliance should be placed on, the fairness, accuracy, completeness or correctness of the information or opinions contained in this release. Such information and opinions are in all events not current after the date of this release. Certain statements made in this release may not be based on historical information or facts and may be 'forward looking statements' based on the currently held beliefs and assumptions of the management of Fermenta Biotech Limited ('Company' or 'FBL' or Fermenta), which are expressed in good faith and in their opinion reasonable, including those relating to the Company's general business plans and strategy, its future financial condition and growth prospects and future developments in its industry and its competitive and regulatory environment. Forward-looking statements involve known and unknown risks, uncertainties and other factors, which may cause the actual results, financial condition, performance or achievements of the Company or industry results to differ materially from the results, financial condition, performance or achievements expressed or implied by such forward-looking statements, including future changes or developments in the Company's business, its competitive environment and political, economic, legal and social conditions. Further, past performance is not necessarily indicative of future results. Given these risks, uncertainties and other factors, viewers of this release are cautioned not to place undue reliance on these forward-looking statements. The Company disclaims any obligation to update these forward-looking statements to reflect future events or developments.
This release is for general information purposes only, without regard to any specific objectives, financial situations or informational needs of any particular person. This release does not constitute an offer or invitation to purchase or subscribe for any securities in any jurisdiction. No part of it should form the basis of or be relied upon in connection with any investment decision or any contract or commitment to purchase or subscribe for any securities. This release is confidential and may not be copied or disseminated, in whole or in part, and in any manner.
For further details, please contact:For Fermenta Biotech Limited:Mr. Prashant Nagre Managing Director
[email protected]
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
an hour ago
- Yahoo
Lazard's Temple Says It's Too Risky to Chase Stocks Now
Lazard Chief Market Strategist Ron Temple says it is too risk to chase stocks either positively or negatively right now amid the geopolitical tensions. He speaks on "Bloomberg Open Interest." Sign in to access your portfolio
Bloomberg
an hour ago
- Bloomberg
Are ESG scores relevant for portfolio returns?
When filtered for data disclosure that is High or Average, companies in the top quintile outperformed companies in the bottom quintile in both the WORLD and WLS indices. To further investigate whether this outperformance can be attributed to information contained in the ESG Scores, and not simply to incidental exposure to other risk factors, we conducted a return attribution analysis using Bloomberg's PORT MAC3 equity risk model. To do this, we form equal-weighted long-short portfolios for both the WORLD Index and WLS Index universes. These portfolios are long the companies in the top quintile and short the companies in the bottom quintile of Figures 5a and 6a, respectively. As shown in Figures 7a and 7b, a substantial portion of the long-short portfolios' returns is not 'explained' by exposures to factors such as Industry, Country, Currency or Equity Style (e.g., value, quality). This unexplained share is termed the 'Selection Effect'. In our back-test, the Selection Effect accounted for 38.3% out of 64.7% of cumulative long-short portfolio returns in the WORLD (High and Average disclosure) universe and 9.3% out of 23.7% of cumulative total returns within the WLS disclosure-filtered universe. Note that this return attribution is based on monthly down-sampled risk exposures from Bloomberg's PORT MAC3 equity risk model, that are produced at a daily frequency. As a result, the attribution results shown here are approximations and may not exactly match analyses performed in PORT .
Bloomberg
an hour ago
- Bloomberg
Lazard's Temple Says It's Too Risky to Chase Stocks Now
Lazard Chief Market Strategist Ron Temple says it is too risk to chase stocks either positively or negatively right now amid the geopolitical tensions. He speaks on "Bloomberg Open Interest." (Source: Bloomberg)
